Brief: Auris Medical Announces Positive Interim Data From Travers Phase 2 Study With Am-125 In Vertigo

Altamira Therapeutics

03/09/2020 13:43

Sept 3 (Reuters) - Auris Medical Holding Ltd  EARS.O :
    * AURIS MEDICAL ANNOUNCES POSITIVE INTERIM DATA FROM TRAVERS
PHASE
2 STUDY WITH AM-125 IN VERTIGO
    * AURIS MEDICAL HOLDING LTD - DOSE DEPENDENT IMPROVEMENT IN
BALANCE TESTS OVER PLACEBO IN PART A OF TRAVERS TRIAL
    * AURIS MEDICAL HOLDING LTD - IMPROVEMENT 1.9 TO 2.4 TIMES
GREATER
WITH HIGHEST DOSE THAN WITH PLACEBO
    * AURIS MEDICAL HOLDING LTD - TRIAL TO PROCEED WITH PART B
TO TEST
AM-125 10 AND 20 MG VERSUS. PLACEBO
    * AURIS MEDICAL HOLDING LTD - POSITIVE RESULTS WERE
SUPPORTED BY
SIMILAR IMPROVEMENTS IN ADDITIONAL EFFICACY MEASURES

Source text for Eikon:  ID:nGNX8NS6WX 
Further company coverage:  EARS.O 

 ((Reuters.Briefs@thomsonreuters.com;))